| [1]Lee B, Thirunavukkarasu K, Zhou L, et al.Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia[J].Nat Genet,1997 ,16(3):307-310.[2]Mundlos S, Otto F, Mundlos C, et al.Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia[J].Cell,1997,89(5):773-779.[3]Baumert U, Golan I, Redlich M, et al.Cleidocranial dysplasia: molecular genetic analysis and phenotypic-based description of a Middle European patient group[J].Am J Med Genet A,2005,139A(2):78-85.[4]Wise GE.Cellular and molecular basis of tooth eruption[J].Orthod Craniofac Res,2009,12(2):67-73.[5]Dorotheou D, Gkantidis N, Karamolegkou M, et al.Tooth eruption: altered gene expression in the dental follicle of patients with cleidocranial dysplasia[J].Orthod Craniofac Res,2013,16(1):20-27.[6]Komori T.Regulation of bone development and extracellular matrix protein genes by RUNX2[J].Cell T1 Res,2010,339(1):189-195.[7]Choi JY, Pratap J, Javed A, et al.Subnuclear targeting of Runx/Cbfa/AML factors is essential for t15-specific differentiation during embryonic development[J].Proc Natl Acad Sci U S A,2001 ,98(15):8650-8655.[8]Komori T, Yagi H, Nomura S, et al.Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts[J].Cell,1997,89(5):755-764.[9]Enomoto H, Shiojiri S, Hoshi K, et al.Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene[J].J Biol Chem,2003 ,278(26):23971-23977 .[10]Akech J, Wixted JJ, Bedard K, et al.Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions[J].Oncogene,2010,29(6):811-821.[11]Felthaus O, Gosau M, Klein S, et al.Dexamethasone-related osteogenic differentiation of dental follicle cells depends on ZBTB16 but not Runx2[J].Cell T3 Res,2014 ,357(3):695-705. |
